Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | FOS | P01100 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029336 | 0.95 | PPARD (0.51) | PPARDMAOBPPARAGRIN1GRIN2B | |
| SCHEMBL6028937 | 0.93 | GRIN2B (0.41) | PPARDMAOBPPARAGRIN1GRIN2B | |
| SCHEMBL6017772 | 0.90 | PPARD (0.55) | PPARDPPARAGRIN1GRIN2BALOX5AP | |
| SCHEMBL5617386 | 0.84 | PPARD (0.64) | PPARDPPARAGRIN1GRIN2BMCL1 | |
| SCHEMBL6029270 | 0.83 | PPARD (0.55) | PPARDMAOBPPARAGRIN1GRIN2B | |
| SCHEMBL5628880 | 0.83 | PPARD (0.49) | PPARDPPARAGRIN1GRIN2BMCL1 | |
| SCHEMBL1550166 | 0.82 | PPARD (0.49) | PPARDMAOBPPARAGSTP1 | |
| SCHEMBL6029063 | 0.82 | PPARD (0.47) | PPARDMAOBPPARAGRIN1GRIN2B | |
| SCHEMBL6017213 | 0.81 | PPARD (0.47) | PPARDMAOBPPARAGRIN1GRIN2B | |
| SCHEMBL6029277 | 0.79 | PPARD (0.51) | PPARDMAOBPPARAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995263-B2 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PPARD 1/4885MAOB 1624/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.